Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.

[1]  Ming‐Lung Yu,et al.  A randomized trial of 24‐ vs. 48‐week courses of PEG interferon α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Ming‐Lung Yu,et al.  Treatment of Chronic Hepatitis C in Southern Taiwan , 2005, Intervirology.

[3]  Ming‐Lung Yu,et al.  Polymorphisms in the interferon-γ gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-α and ribavirin , 2005 .

[4]  T. Berg,et al.  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[5]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[6]  M. Lai,et al.  Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan , 2005, Journal of viral hepatitis.

[7]  Ming‐Lung Yu,et al.  High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study , 2005, BMC infectious diseases.

[8]  Ming‐Lung Yu,et al.  Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy , 2005, Antiviral therapy.

[9]  K. Bjøro,et al.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study , 2004, Hepatology.

[10]  Ming‐Lung Yu,et al.  Randomized trial of three different regimens for 24 weeks for re‐treatment of chronic hepatitis C patients who failed to respond to interferon‐α monotherapy in Taiwan , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[11]  P Martus,et al.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences , 2004, Gut.

[12]  Ming‐Lung Yu,et al.  A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. , 2004, Antiviral research.

[13]  K. Reddy,et al.  Peginterferon alfa‐2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 , 2004, Hepatology.

[14]  P. Killenberg,et al.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.

[15]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[16]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[17]  Ming‐Lung Yu,et al.  Human Leukocyte Antigen Class I and Ii Alleles and Response to Interferon-A Treatment, in Taiwanese Patients with Chronic Hepatitis C Virus Infection , 2003 .

[18]  C. Changchien,et al.  Mutations in the NS5A and E2‐PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin , 2003, Journal of viral hepatitis.

[19]  J. Hoofnagle,et al.  Optimal therapy of hepatitis C , 2002, Hepatology.

[20]  G. Ippolito,et al.  ISDR Pattern and Evolution in Patients with Chronic Hepatitis C Treated with Standard Or Peg-Ifn plus Ribavirin , 2002, Antiviral therapy.

[21]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[22]  J. Goedert,et al.  Racial differences in HLA class II associations with hepatitis C virus outcomes. , 2001, The Journal of infectious diseases.

[23]  T. Layden,et al.  How can mathematics help us understand HCV? , 2001, Gastroenterology.

[24]  A. Neumann,et al.  Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. , 2001, Gastroenterology.

[25]  J. Pawlotsky,et al.  Standardization of Hepatitis C Virus RNA Quantification , 2000, Hepatology.

[26]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[27]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[28]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[29]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[30]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[31]  Ding‐Shinn Chen,et al.  Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. , 1996, Gastroenterology.

[32]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[33]  J. Schmidt,et al.  Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.

[34]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[35]  M. Sakamoto,et al.  Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.

[36]  D. Cox,et al.  Statistical significance tests. , 1982, British journal of clinical pharmacology.

[37]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[38]  Ming‐Lung Yu,et al.  Tumor Necrosis Factor–α Promoter Polymorphism at Position −308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection , 2006 .

[39]  Kwang-Hyub Han,et al.  [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C]. , 2004, The Korean journal of hepatology.

[40]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[41]  P. Marcellin.  EASL International Consensus Conference on Hepatitis C , 1999 .